Serum level of fibroblast growth factor 21 is independently associated with acute myocardial infarction

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Zhang, Wenduo ^a   Chu, Songyun ^b   Ding, Wenhui ^b   Wang, Fang ^a  

^a BEIJING HOSPITAL   (China)

^b PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; FIBROBLAST GROWTH FACTOR 21; FIBROBLAST GROWTH FACTOR;

ACUTE HEART INFARCTION; ADULT; ARTICLE; CHINESE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HEART PROTECTION; HEART REINFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION; AGED; BLOOD; CASE CONTROL STUDY; ELECTROCARDIOGRAPHY; MIDDLE AGED; MORTALITY; MYOCARDIAL INFARCTION; NUTRITIONAL ASSESSMENT; RISK FACTOR; TIME FACTOR;

AGED; BIOMARKERS; CASE-CONTROL STUDIES; ELECTROCARDIOGRAPHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NUTRITION ASSESSMENT; RISK FACTORS; TIME FACTORS;

EID: 84939177187     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0129791     Document Type: Article

References (26)

1. Nishimura T, Nakatake Y, Konishi M, Itoh N (2000) Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta 1492: 203-206. PMID: 10858549
2. Li H, Zhang J, Jia W (2013) Fibroblast growth factor 21: a novel metabolic regulator from pharmacology to physiology. Front Med 7: 25-30. doi: 10.1007/s11684-013-0244-8 PMID: 23358894
3. Li H, Bao Y, Xu A, Pan X, Lu J, Wu H, et al. (2009) Serum fibroblast growth factor 21 is associated with adverse lipid profiles and gamma-glutamyltransferase but not insulin sensitivity in Chinese subjects. J Clin Endocrinol Metab 94: 2151-2156. doi: 10.1210/jc.2008-2331 PMID: 19318452
4. Mraz M, Bartlova M, Lacinova Z, Michalsky D, Kasalicky M, Haluzikova D, et al. (2009) Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. Clin Endocrinol (Oxf) 71: 369-375. doi: 10.1111/j.1365-2265.2008.03502.x PMID: 19702724
5. Chow WS, Xu A, Woo YC, Tso AW, Cheung SC, Fong CH, et al. (2013) Serum fibroblast growth factor-21 levels are associated with carotid atherosclerosis independent of established cardiovascular risk factors. Arterioscler Thromb Vasc Biol 33: 2454-2459. doi: 10.1161/ATVBAHA.113.301599 PMID: 23887638
6. Lin Z, Wu Z, Yin X, Liu Y, Yan X, Lin S, et al. (2010) Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile. PLoS One 5: e15534. doi: 10.1371/journal.pone.0015534 PMID: 21206918
7. Semba RD, Crasto C, Strait J, Sun K, Schaumberg DA, Ferrucci L, et al. (2013) Elevated serum fibroblast growth factor 21 is associated with hypertension in community-dwelling adults. J Hum Hypertens 27: 397-399. doi: 10.1038/jhh.2012.52 PMID: 23190795
8. Ong KL, Januszewski AS, O'Connell R, Jenkins AJ, Xu A, Sullivan DR, et al. (2015) The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study. Diabetologia. Diabetologia 58(3):464-73.
9. Lenart-Lipińska M, Matyjaszek-Matuszek B, Gernand W, Nowakowski A, Solski J (2013) Serum fibroblast growth factor 21 is predictive of combined cardiovascular morbidity and mortality in patients with type 2 diabetes at a relatively short-term follow-up. Diabetes Res Clin Pract 101: 194-200. doi: 10.1016/j.diabres.2013.04.010 PMID: 23768789
10. Patel V, Adya R, Chen J, Ramanjaneya M, Bari MF, Bhudia SK, et al. (2014) Insights into the cardioprotective effects of FGF21 in lean and obese rat hearts. PLoS One 9: e87102. doi: 10.1371/journal. pone.0087102 PMID: 24498293
11. Thygesen K (2012) Third universal definition of myocardial infarction. Circulation 126: 2020-2035. doi: 10.1161/CIR.0b013e31826e1058 PMID: 22923432
12. 2013 ACCF/AHA Guideline for the management of ST-elevation myocardial infarction. JACC 61: e78-140. doi: 10.1016/j.jacc.2012.11.019 PMID: 23256914
13. 2012 ACCF/AHA Focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction. Circulation 126: 875-910. doi: 10.1161/CIR.0b013e318256f1e0 PMID: 22800849
14. American Diabetes Association (2011) Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. Jan; 34(Suppl 1): S62-S69. doi: 10.2337/dc11-S062 PMID: 21193628
15. Bethesda (MD): National Heart, Lung, and Blood Institute (US) (2004) The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National High Blood Pressure Education Program. Aug. Report No.: 04-5230.
16. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) JAMA 285: 2486-2497. PMID: 11368702
17. Shen Y, Ma X, Zhou J, Pan X, Hao Y, Zhou M, et al. (2013) Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease. Cardiovasc Diabetol 12: 124-131. doi: 10.1186/1475-2840-12-124 PMID: 23981342
18. Mayr A, Mair J, Schocke M, Klug G, Pedarnig K, Haubner BJ, et al. (2011) Predictive value of NT-pro BNP after acute myocardial infarction: relation with acute and chronic infarct size and myocardial function. Int J Cardiol 17: 118-123.
19. Jensen JK, Atar D, Kristensen SR, Mickley H, Januzzi JL Jr (2009) Usefulness of natriuretic peptide testing for long-term risk assessment following acute ischemic stroke. Am J Cardiol 104: 287-291. doi: 10.1016/j.amjcard.2009.03.029 PMID: 19576362
20. Fukuyama H, Ishida T, Tachibana H, Nakagawa H, Iwasaku M, Saigusa M, et al. (2011) Validation of scoring systems for predicting severe community-acquired pneumonia. Intern Med 50: 1917-1922. PMID: 21921369
21. Hong YJ, Ahn Y, Sim DS, Yoon NS, Yoon HJ, Kim KH, et al. (2009) Relation between N-terminal pro-Btype natriuretic peptide and coronary plaque components in patients with acute coronary syndrome: virtual histology-intravascular ultrasound analysis. Coron Artery Dis 20: 518-524. doi: 10.1097/MCA.0b013e32832a196e PMID: 19838110
22. Lu Y, Liu JH, Zhang LK, Du J, Zeng XJ, Hao G, et al. (2010) Fibroblast growth factor 21 as a possible endogenous factor inhibits apoptosis in cardiac endothelial cell. Chin Med J 123: 3417-3422. PMID: 22166524
23. Planavila A, Redondo I, Hondares E, Vinciguerra M, Munts C, Iglesias R, et al. (2013) Fibroblast growth factor 21 protects against cardiac hypertrophy in mice. Nat Commun 4: 2019. doi: 10.1038/ncomms3019 PMID: 23771152
24. Reinehr T, Woelfle J, Wunsch R, Roth CL (2012) Fibroblast growth factor 21 (FGF-21) and its relation to obesity, metabolic syndrome, and nonalcoholic fatty liver in children: a longitudinal analysis. J Clin Endocrinol Metab 97: 2143-2150. doi: 10.1210/jc.2012-1221 PMID: 22438225
25. Semba RD, Sun K, Egan JM, Crasto C, Carlson OD, Ferrucci L, et al. (2012) Relationship of serum fibroblast growth factor 21 with abnormal glucose metabolism and insulin resistance: the Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 97: 1375-1382. doi: 10.1210/jc.2011-2823 PMID: 22344195
26. Liu SQ, Tefft BJ, Roberts DT, Zhang LQ, Ren Y, Li YC, et al. (2012) Cardioprotective proteins upregulated in the liver in response to experimental myocardial ischemia. Am J Physiol Heart Circ Physiol 303: H1446-H1458. doi: 10.1152/ajpheart.00362.2012 PMID: 23064833